Brachy boost: the gold standard for progression-free survival of high-risk prostate cancer

Several randomized clinical trials have established the superior oncological outcomes of the combination of external beam radiotherapy with a high-dose-rate brachytherapy boost (see this link). … READ MORE …

EBRT works better with ADT for intermediate- and high-risk prostate cancer

The EORTC trial 22991 was designed and implemented to compare external beam radiation therapy (EBRT) + short-term androgen deprivation therapy (ADT) to EBRT alone as first-line therapy in patients with intermediate- and high-risk prostate cancer. … READ MORE …

Low PSA + Gleason 8 to 10 disease predictive of higher risk, worse survival

It has been hypothesized for some time that men diagnosed with a low PSA level (i.e., < 4.0 ng/ml) but a high Gleason score (of 8, 9, or 10) are at elevated risk for more advanced disease and a shorter survival time than some others. … READ MORE …

The “best” form of first-line treatment for clinically significant, localized prostate cancer

From the perspective of the disinterested observer, one of the very least edifying aspects of issues related to the management of prostate cancer has been the nearly 50-year-long “discussion” between the urology community and the radiation oncology community about the most appropriate way(s) to treat localized disease. … READ MORE …

Brachytherapy boost may lower mortality rate in high-risk patients

The ASCENDE-RT randomized clinical trial demonstrated that the combination of external beam radiation therapy with a brachytherapy boost (EBRT + BT) significantly reduced biochemical progression-free survival. … READ MORE …

Radiation therapy may improve survival even when PSA ≥ 75 ml/ml

Sometimes, when patients originally present with very high PSA levels, a negative bone scan, and a negative CT scan, they are put on permanent androgen deprivation  therapy (ADT) because the doctor just assumes it is micrometastatic. … READ MORE …

Elevated cholesterol levels and risk for high-grade prostate cancer

A new report from a Scottish research team offers evidence that high plasma cholesterol levels are associated with an increased risk for a diagnosis of high-grade prostate cancer. … READ MORE …